TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01008254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical prompt
Description: Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed musical prompt
Description: Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No musical prompt
Description: No intervention.
Study: NCT02344472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Description: endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: endocrine therapy
Study: NCT01213251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Site Pacing
Description: Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Site Pacing
Description: Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
Study: NCT01121029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
Study: NCT06098352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEBL Continuous Performance Task
Description: A PEBL version of the Conners Continuous Performance Task
Study: NCT03811119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MANTA vascular closure device
Description: Collagen based vascular closure device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture based vascular closure device
Description: Suture based vascular closure device (ProGlide)
Study: NCT01557244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine PR 4 mg
Description: Fesoterodine 4 mg tablet once daily for 24 weeks
Study: NCT03833427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.
Study: NCT01663467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Description: Ginexin-F 80mg tablet will be given twice a day for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba
Description: Ginexin-F 80mg tablet will be given twice a day for 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified TRT
Description: modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months.
Study: NCT04220229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy
Study: NCT01557244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine PR 8 mg
Description: Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
Study: NCT02836275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion/Perfusion-weighted Magnetic Resonance Imaging
Study: NCT03387683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: dapagliflozin 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match dapagliflozin
Study: NCT03583723

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy Group
Description: Patients will be immobilized with customized devices. Either four-dimensional CT or slow CT images using a multislice CT scanner will be acquired to evaluate internal target motion. Initially, gross tumor volume (GTV) will be determined in the maximum intensity projection on the initial size of the tumor and involved lymph nodal sites defined as PET-positive nodes and/or a node diameter greater than 1 cm, clinical target volume (CTV) will be defined as equal to the GTV plus node-positive stations and hilar stations, and planning target volume (PTV) will be created equal to the CTV plus a 0.5-cm safety margin. Treatment will be performed with a linear accelerator in a photon regimen, with a 6-to 15-megavolt (MV) nominal energy and three-dimensional (3D) conformal technique.
Study: NCT00629772

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
Study: NCT02778867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 Food Elimination Diet Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6 Food Elimination Diet Therapy
Study: NCT00629772

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infliximab
Description: Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
Study: NCT00729287

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Description: Given orally
Study: NCT02467582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05927480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio distraction
Description: Music on an mp3 player will be provided to the patient for them to listen to while having the traction pin placed.
Study: NCT01682538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitisinone, capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone, suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone, suspension
Study: NCT00729287

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT04108702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality heart
Description: Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off SYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual reality control
Description: Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off ASYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard therapy
Description: Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
Study: NCT02778867

Intervention type: OTHER
Group type: OTHER
Intervention: 6 Food Elimination Diet (after 1FED failure)

Intervention type: DRUG
Group type: OTHER
Intervention: Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
Study: NCT03532971

Intervention type: OTHER
Intervention: Symptom index questionnaire
Description: A survey administered to identify the symptoms of the patient

Intervention type: DIAGNOSTIC_TEST
Intervention: BK polyomavirus PCR
Description: quantitative PCR testing

Intervention type: OTHER
Intervention: quality of life questionnaires
Description: Standard questionnaires validated for HCT recipients
Study: NCT00540969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery
Description: Patients undergo cryosurgery using guidance from CT scan or ultrasound

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo radiotherapy for 1 week
Study: NCT03047993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutaminase Inhibitor CB-839
Description: Given PO
Study: NCT02169284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01889797

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: Rituximab
Description: Rituximab 375 mg/m² IV x 4 weekly doses.
Study: NCT03716167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Summus Laser
Description: infrared laser treatment
Study: NCT02169284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT03716167

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Summus Laser Sham
Description: non-infrared light
Study: NCT01557244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine PR 8 mg
Description: Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
Study: NCT02169284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03117036

Intervention type: DRUG
Intervention: Chemotherapy
Description: Systemic chemotherapy with curative intent
Study: NCT01557244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fesoterodine PR
Description: Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
Study: NCT02169284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo TURBT or cystectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo TURBT or cystectomy
Study: NCT03048916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general swallowing therapy
Description: including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.

Intervention type: OTHER
Group type: OTHER
Intervention: general swallowing therapy
Description: including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NMES therapy
Description: he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES therapy
Description: he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
Study: NCT01889797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm B: GA101
Description: GA101 1,000 mg (flat dose) IV x 4 weekly doses.
Study: NCT02259348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given IV or subcutaneously (SQ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Given SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study: NCT01008150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study: NCT02725892

Intervention type: OTHER
Intervention: NIS observational stud
Description: NIS observational study : Epidemiologic registry
Study: NCT02259348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cell therapy
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell depleted HPC transplant
Description: T-cell depleted hematopoietic stem cells will be infused on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD45RA-depleted HPC transplant
Description: CD45RA depleted stem cells will be infused on day 1.
Study: NCT05344287

Intervention type: OTHER
Intervention: Typical American Diet
Description: Participants self-reported adherence to a typical American diet prior to enrolling in the study. This factor determined cross-sectional group allocation.

Intervention type: OTHER
Intervention: Plant-Based Diet
Description: Participants self-reported adherence to a 100% plant-based diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
Study: NCT00892749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study: NCT00057967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
Study: NCT03157869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Simulated
Description: Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
Study: NCT02174276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: TDF 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: TDF 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: TDF 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: TDF 300 mg tablet administered orally once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
Study: NCT01557244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine BIC 2 mg
Description: Fesoterodine BIC 2 mg tablet once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine BIC 4 mg
Description: Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
Study: NCT02174276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses